SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-009637
Filing Date
2023-03-30
Accepted
2023-03-30 12:31:55
Documents
13
Period of Report
2023-03-30
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45545
2 ex3-1.htm EX-3.1 9144
  Complete submission text file 0001493152-23-009637.txt   236080

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ensc-20230330.xsd EX-101.SCH 3224
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ensc-20230330_lab.xml EX-101.LAB 34240
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ensc-20230330_pre.xml EX-101.PRE 22357
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3844
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

IRS No.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 23778661
SIC: 2834 Pharmaceutical Preparations